Literature DB >> 7493451

Vth International Symposium on Sjögren's syndrome. Clinical aspects and therapy.

R I Fox1.   

Abstract

There is increasing awareness that sicca syndrome can lead to ocular, oral and systemic complications. However, a wide variety of pathogenetic processes may lead to the same end result of diminished glandular secretion. Recognition of these different etiologies will lead to improved therapies. On the one hand, an active inflammatory/autoimmune process may respond to immunomodulatory drugs. On the other hands, processes that predominantly involve "neuroendocrine" dysfunction (unrelated to immune activity) of the gland will require a different approach.

Entities:  

Mesh:

Year:  1995        PMID: 7493451     DOI: 10.1007/bf03342633

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  27 in total

1.  Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community.

Authors:  C Vitali; S Bombardieri; H M Moutsopoulos; G Balestrieri; W Bencivelli; R M Bernstein; K B Bjerrum; S Braga; J Coll; S de Vita
Journal:  Arthritis Rheum       Date:  1993-03

Review 2.  Criteria for diagnosis of Sjögren's syndrome.

Authors:  R I Fox; I Saito
Journal:  Rheum Dis Clin North Am       Date:  1994-05       Impact factor: 2.670

3.  Type II essential mixed cryoglobulinaemia: presentation, treatment and outcome in 13 patients.

Authors:  A H Frankel; D R Singer; C G Winearls; D J Evans; A J Rees; C D Pusey
Journal:  Q J Med       Date:  1992-02

4.  Detection of clonally expanded salivary gland lymphocytes in Sjögren's syndrome.

Authors:  B Freimark; R Fantozzi; R Bone; G Bordin; R Fox
Journal:  Arthritis Rheum       Date:  1989-07

5.  Molecular characterization of a major autoantibody-associated cross-reactive idiotype in Sjogren's syndrome.

Authors:  T J Kipps; E Tomhave; P P Chen; R I Fox
Journal:  J Immunol       Date:  1989-06-15       Impact factor: 5.422

6.  Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial.

Authors:  A A Kruize; R J Hené; C G Kallenberg; O P van Bijsterveld; A van der Heide; L Kater; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1993-05       Impact factor: 19.103

7.  Treatment of primary Sjögren's syndrome with hydroxychloroquine.

Authors:  R I Fox; E Chan; L Benton; S Fong; M Friedlaender; F V Howell
Journal:  Am J Med       Date:  1988-10-14       Impact factor: 4.965

8.  The European Community Study Group on diagnostic criteria for Sjögren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren's syndrome.

Authors:  C Vitali; H M Moutsopoulos; S Bombardieri
Journal:  Ann Rheum Dis       Date:  1994-10       Impact factor: 19.103

9.  Pilocarpine for the treatment of xerostomia associated with salivary gland dysfunction.

Authors:  P C Fox; P F van der Ven; B J Baum; I D Mandel
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1986-03

10.  The polymerase chain reaction detects B cell clonalities in patients with Sjögren's syndrome and suspected malignant lymphoma.

Authors:  S De Vita; G Ferraccioli; V De Re; R Dolcetti; A Carbone; E Bartoli; M Boiocchi
Journal:  J Rheumatol       Date:  1994-08       Impact factor: 4.666

View more
  2 in total

1.  Cardiac manifestations in primary Sjögren's syndrome.

Authors:  M Gyöngyösi; G Pokorny; Z Jambrik; L Kovács; A Kovács; E Makula; M Csanády
Journal:  Ann Rheum Dis       Date:  1996-07       Impact factor: 19.103

2.  Fatigue in primary Sjögren's syndrome.

Authors:  P J Barendregt; M R Visser; E M Smets; J H Tulen; A H van den Meiracker; F Boomsma; H M Markusse
Journal:  Ann Rheum Dis       Date:  1998-05       Impact factor: 19.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.